Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | ALB | P02768 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6830454 | 1.00 | TK1 (0.43) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL5052901 | 0.87 | PYGM (0.46) | TK1LMNABLMALDH1A1POLB | |
| SCHEMBL29364921 | 0.85 | TK1 (0.45) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL135210 | 0.84 | TK1 (0.44) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL4809531 | 0.84 | TK1 (0.44) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL16187026 | 0.84 | TK1 (0.44) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL8438314 | 0.83 | TK1 (0.43) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL7537552 | 0.83 | TK1 (0.43) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL5849101 | 0.83 | TK1 (0.43) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL2294 | 0.83 | TK1 (0.43) | TK1LMNAALBBLMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638048-A1 | NUCLEIC ACIDSBUILDING BLOCKS AND METHODS FOR THE SYNTHESIS OF 5-HYDROXYMETHYLCYTOSINE-CONTAINING | Ludwig-Maximilians-Universität München (DE) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237697-A1 | BUILDING BLOCKS AND METHODS FOR THE SYNTHESIS OF 5-HYDROXYMETHYLCYTOSINE-CONTAINING NUCLEIC ACIDS | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2013-09-12 | — | — | US | disclosed |
| WO-2012062907-A1 | NUCLEIC ACIDSBUILDING BLOCKS AND METHODS FOR THE SYNTHESIS OF 5-HYDROXYMETHYLCYTOSINE-CONTAINING | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2012-05-18 | — | — | WO | disclosed |
| US-6743902-B1 | FOR USE IN ANTISENSE THERAPY FOR ENHANCING NUCLEASE RESISTANCE AND CELLULAR UPTAKE | VALEANT PHARMACEUTICALS INTERNATIONAL | 2004-06-01 | — | — | US | disclosed |
| US-6191266-B1 | MODIFIED TO COMPRISE SUBSTITUTIONS AT POSITIONS C1', C3', C4' OR C5' OF THE SUGAR MOIETY OF THE NUCLEOSIDE, INCLUDING AN OPTIONAL 3' PHOSPHOROAMIDITE GROUP; USE IN MAKING NUCLEASE RESISTANT OLIGONUCLEOTIDES FOR ANTISENSE THERAPY | ICN PHARMACEUTICALS, INC. | 2001-02-20 | — | — | US | disclosed |
| EP-0789706-A4 | SUGAR MODIFIED NUCLEOSIDES AND THEIR USE FOR SYNTHESIS OF OLIGONUCLEOTIDES | ICN PHARMACEUTICALS (US) | 1999-08-11 | — | — | EP | disclosed |
| US-5712378-A | SUGAR MOLECULE IS SUBSTITUTED WITH HYDROCARBON OR SUBSTITUTED HYDROCARBON GROUPS, ANTISENSE AGENTS | ICN PHARMACEUTICALS (US) | 1998-01-27 | — | — | US | disclosed |
| US-5681940-A | CONTAIN TETRAHYDROTHIOPHENE OR PYROLIDINE RINGS | ICN PHARMACEUTICALS (US) | 1997-10-28 | — | — | US | disclosed |
| EP-0789706-A1 | SUGAR MODIFIED NUCLEOSIDES AND THEIR USE FOR SYNTHESIS OF OLIGONUCLEOTIDES | ICN PHARMACEUTICALS (US) | 1997-08-20 | — | — | EP | disclosed |
| WO-1996014329-A1 | SUGAR MODIFIED NUCLEOSIDES AND THEIR USE FOR SYNTHESIS OF OLIGONUCLEOTIDES | ICN PHARMACEUTICALS (US) | 1996-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237697-A1 | BUILDING BLOCKS AND METHODS FOR THE SYNTHESIS OF 5-HYDROXYMETHYLCYTOSINE-CONTAINING NUCLEIC ACIDS | RNGTT, NSUN2, NT5C3B | TK1 411/4885LMNA 1368/4885ALB 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.